For Q2 FY2026 ended March 31, 2026, Cencora reported revenue of $78.4 billion, up 3.8% year-over-year. Net income surged 128.6% to $1.64 billion, while diluted EPS rose 128.3% to $8.40. Operating income increased 10.3% to $1.14 billion. The company held $2.18 billion in cash, $3.40 billion in equity, and $12.39 billion in long-term debt.
•Revenue grew 3.8% YoY to $78.4 billion.
•Net income jumped 128.6% to $1.64 billion.
•Diluted EPS increased 128.3% to $8.40.
•Operating income rose 10.3% to $1.14 billion.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and customers.
Its portfolio also includes distributes plasma and blood products, vaccines, and specialty pharmaceutical products, provides pharmacy management, staffing, and consulting services, supply management software to retail and institutional healthcare providers, packaging solutions to institutional and retail healthcare providers, clinical trial support, product post-approval, and commercialization support services, data analytics, outcomes research, and services for biotechnology and pharmaceutical manufacturers, pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and products to the companion animal and production animal markets, sales force services to manufacturers, and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics.
Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services. Its portfolio also includes distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals, and offers specialty transportation and logistics services for the biopharmaceutical industry. Founded in 1871 and headquartered in Conshohocken, Pennsylvania, Cencora was formerly known as AmerisourceBergen Corporation before rebranding in August 2023.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. Through its U.S. Healthcare Solutions segment, it distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide range of customers including acute care hospitals, chain and independent retail pharmacies, mail order pharmacies, medical clinics, and long-term care facilities. The segment also distributes plasma and blood products, vaccines, and specialty pharmaceuticals, and offers pharmacy management, staffing, consulting, and supply management software. Additionally, it provides packaging solutions, clinical trial support, post-approval services, data analytics, and outcomes research for biotechnology and pharmaceutical manufacturers. Its International Healthcare Solutions segment handles pharmaceutical wholesale and global commercialization services, distributing pharmaceuticals and other healthcare products internationally.
Where is Cencora (COR) listed and in which currency?
Cencora, Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol COR. The company's financial reporting is in U.S. dollars (USD), as it is headquartered in the United States. Being listed on the NYSE provides investors with access to one of the world's largest and most liquid stock exchanges, and the use of USD facilitates straightforward comparison with other U.S.-based companies in the healthcare sector.
What sector and industry does Cencora (COR) operate in?
Cencora, Inc. operates in the Healthcare sector, specifically within the Medical Distribution industry. This means the company is primarily involved in the distribution of pharmaceutical products and healthcare supplies to various healthcare providers, rather than manufacturing drugs or providing direct patient care. As a medical distributor, Cencora plays a critical role in the healthcare supply chain, ensuring that pharmacies, hospitals, clinics, and other healthcare facilities have access to the medications and supplies they need. The company's operations span both the United States and international markets, making it a key player in global pharmaceutical logistics.
What geographic markets does Cencora (COR) serve?
Cencora, Inc. serves both the United States and international markets. Its U.S. Healthcare Solutions segment covers the domestic market, distributing to acute care hospitals, health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care facilities, and alternate site pharmacies. The International Healthcare Solutions segment provides pharmaceutical wholesale and global commercialization services outside the U.S., distributing pharmaceuticals and other healthcare products to various countries. While the summary does not specify exact international locations, the company's global reach includes services for biotechnology and pharmaceutical manufacturers, as well as sales force services to physicians specializing in disease states like oncology, and services to hospitals and dialysis clinics.
How does Cencora (COR) generate revenue?
Cencora generates revenue primarily through the distribution of pharmaceutical products and healthcare supplies. Its U.S. Healthcare Solutions segment earns income by distributing generic and injectable drugs, over-the-counter products, home healthcare supplies, plasma and blood products, vaccines, and specialty pharmaceuticals to a diverse customer base. Additionally, it offers value-added services such as pharmacy management, staffing, consulting, supply management software, packaging solutions, clinical trial support, and data analytics, which generate service fees. The International Healthcare Solutions segment contributes through pharmaceutical wholesale and global commercialization services, including distribution and sales force services to manufacturers and healthcare providers. The company also serves the companion animal and production animal markets with pharmaceuticals, vaccines, and diagnostics, indicating a diversified revenue stream across human and animal health.